GSK2606414 is an orally available, potent, and selective PERK inhibitor. GSK2606414 inhibits PERK activation in cells and inhibits the growth of a human tumor xenograft in mice. Protein kinase R (PKR)-like endoplasmic reticulum kinase (PERK) is activated in response to a variety of endoplasmic reticulum stresses implicated in numerous disease states. Evidence that PERK is implicated in tumorigenesis and cancer cell survival stimulated our search for small molecule inhibitors.
Related Prodcuts:
Etoposide; Etoposide phosphate; ML-323; BMH-21; Nexturastat A; TMP269; ELR510444; Chidamide; Inauhzin; CW069; Purvalanol A; Purvalanol B; JW55; Tenovin-6; Tenovin-6 HCL; RKI-1447; AZD2461; Tasquinimod